Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Novo Nordisk A/S ADR (NVO)

Novo Nordisk A/S ADR (NVO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 569,692,224
  • Shares Outstanding, K 4,487,532
  • Annual Sales, $ 33,724 M
  • Annual Income, $ 12,151 M
  • 60-Month Beta 0.42
  • Price/Sales 16.70
  • Price/Cash Flow 41.08
  • Price/Book 34.19
Trade NVO with:

Options Overview Details

View History
  • Implied Volatility 28.97% ( +1.56%)
  • Historical Volatility 31.61%
  • IV Percentile 38%
  • IV Rank 21.82%
  • IV High 49.01% on 08/05/24
  • IV Low 23.37% on 06/12/24
  • Put/Call Vol Ratio 1.02
  • Today's Volume 22,568
  • Volume Avg (30-Day) 20,085
  • Put/Call OI Ratio 1.00
  • Today's Open Interest 247,628
  • Open Int (30-Day) 263,113

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate 0.91
  • Number of Estimates 4
  • High Estimate 0.97
  • Low Estimate 0.87
  • Prior Year 0.73
  • Growth Rate Est. (year over year) +24.66%

Price Performance

See More
Period Period Low Period High Performance
1-Month
122.94 +1.11%
on 09/23/24
139.74 -11.05%
on 08/30/24
-11.00 (-8.13%)
since 08/26/24
3-Month
118.80 +4.63%
on 08/07/24
145.99 -14.86%
on 07/01/24
-19.37 (-13.48%)
since 06/26/24
52-Week
86.96 +42.94%
on 10/03/23
148.15 -16.10%
on 06/25/24
+32.51 (+35.42%)
since 09/26/23

Most Recent Stories

More News
Forget Novo Nordisk, Buy This Magnificent Dividend Stock Instead

Even the mighty Novo Nordisk can't hold a candle to its peer in this area.

NVO : 124.30 (-2.09%)
ABBV : 191.90 (+0.33%)
Novo Nordisk's $600 Million Gambit Could Be a Game Changer for the Stock. Here's Why.

The healthcare company's pivot into a new set of technologies will have many implications for the stock.

NVO : 124.30 (-2.09%)
LLY : 909.32 (-1.65%)
Novo Nordisk Faces Pressure Over High U.S. Drug Prices

U.S. Senator Bernie Sanders intensified pressure on Novo Nordisk (NVO) to lower the prices of its popular diabetes and weight-loss drugs, Ozempic and Wegovy, during a Senate hearing. Sanders revealed that...

CVS : 59.01 (+0.63%)
CI : 344.99 (-1.11%)
NVO : 124.30 (-2.09%)
UNH : 574.81 (-0.26%)
Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges

Novo Nordisk has received both good and bad news recently when it comes to weight loss and diabetes drugs. So, where does the firm stand now?

NVO : 124.30 (-2.09%)
LLY : 909.32 (-1.65%)
GPCR : 41.53 (-1.00%)
SNY : 57.00 (+0.62%)
2 Weight-Loss Stocks That Could Rocket Higher This Year

Upcoming clinical trial results could push these stocks through the roof before 2024 is finished.

NVO : 124.30 (-2.09%)
LLY : 909.32 (-1.65%)
AMGN : 319.10 (+1.99%)
3 Stocks That Could Rise on European Bank Interest Rate Cuts

The European Central Bank cut interest rates for the second time in about three months prior the FOMC's interest rate announcement, European stocks may benefit.

NVDA : 124.04 (+0.43%)
AVGO : 178.09 (+1.46%)
NVO : 124.30 (-2.09%)
KRRO : 34.75 (+0.87%)
IFNNY : 34.5000 (+5.25%)
ASML : 852.44 (+4.19%)
Snag This Biotech Stock Before November, Here's Why

With Viking Therapeutics making a splash in the weight-loss drug arena, one analyst is encouraging investors to snap up the stock before a November catalyst.

VKTX : 62.32 (-1.28%)
NVO : 124.30 (-2.09%)
LLY : 909.32 (-1.65%)
Why Novo Nordisk Stock Fell While Eli Lilly and Viking Therapeutics Bumped Higher Today

The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.

VKTX : 62.32 (-1.28%)
NVO : 124.30 (-2.09%)
LLY : 909.32 (-1.65%)
Sanofi Stock Up Almost 23% in 3 Months: Buy, Sell or Hold?

Sanofi’s SNY stock has gained 22.7% in the past three months compared with an increase of 2.9% for the industry. The stock has also outperformed the sector and the S&P 500 index as seen in the chart...

SNY : 57.00 (+0.62%)
AZN : 78.18 (+0.83%)
NVO : 124.30 (-2.09%)
LLY : 909.32 (-1.65%)
Pfizer Stock Rises 7.3% in 3 Months: Should You Invest Now?

Pfizer PFE stock has risen 7.3% in the past three months compared with an increase of 2.9% for the industry. The stock has also outperformed the sector as well as the S&P 500, as seen in the chart below.PFE...

PFE : 28.97 (+0.14%)
NVO : 124.30 (-2.09%)
LLY : 909.32 (-1.65%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Strengthening short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Bagsv'rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care...

See More

Key Turning Points

3rd Resistance Point 126.93
2nd Resistance Point 126.27
1st Resistance Point 125.29
Last Price 124.30
1st Support Level 123.65
2nd Support Level 122.99
3rd Support Level 122.01

See More

52-Week High 148.15
Fibonacci 61.8% 124.78
Last Price 124.30
Fibonacci 50% 117.55
Fibonacci 38.2% 110.33
52-Week Low 86.96

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar